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A protease purified from the venom of the elapid 
snake Nqju nqju oxiunu converts human  blood  coagula- 
tion factor Va into a molecule (factor Va,) with greatly 
reduced cofactor activity. Polyacrylamide gel electro- 
phoresis in the presence of sodium  dodecyl sulfate re- 
vealed that  the venom protease cleaved a small peptide 
from the heavy chain of factor Va and reduced the ap- 
parent M ,  from 105,000 to 101,000. This peptide was  iso- 
lated by high performance liquid chromatography on a 
reversed-phase column.  Amino acid sequence analysis of 
the peptide indicated that the venom  enzyme  cleaved 
the peptide bond  between  HisesZ and Aspes3, thus remov- 
ing 27 amino acids from the carboxyl-terminal part of 
the heavy chain. The  cofactor activities of factors Va and 
Va, were  compared by measuring their abilities to sup- 
port factor Xa-catalyzed prothrombin activation in  the 
presence of phospholipids and calcium  ions.  Both factor 
Va molecules stimulated the binding of factor Xa to 
negatively charged phospholipids.  However, the 
amounts of factor Va required for half-maximal incorpo- 
ration of factor Xa into the membrane-bound factor 
Xa-Va complex were much lower for native factor Va 
(0.25 m) than for factor Va,, (2.01 m). At saturating 
concentrations of factor Va or factor Va, the kEat values 
for prothrombin activation were 114 s-l for factor Va and 
128 s-l for factor Va,. The K,,, values for prothrombin 
determined under these conditions were 0.24 and 0.83 
p~ for prothrombinase complexes with native factor Va 
and factor Va, respectively.  Direct binding studies re- 
vealed that factors Va and Va, bind with equal affinity 
to phospholipids.  These data indicate that factor Va, is 
impaired in  its ability to interact with factor Xa and 
prothrombin. Together with the  structural  data  this im- 
plies that  the carboxyl-terminal A~p'~-Arg '~~ domain of 
the heavy chain is required for optimal interaction of 
factor Va with factor Xa and prothrombin. 
Blood coagulation  factor Vis a  single-chain  glycoprotein with 
a molecular  weight of 330,000 (1, 2)  that  contains  three differ- 
ent  types of protein  domains (A, B, and C) arranged  in  the  order 
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Al-A2-B-A3-Cl-C2 (3, 4). Activation of human factor V by 
thrombin results in the removal of the major part of the B 
domain  and  the  generation of factor Va, a molecule that con- 
sists of a heavy  chain  (containing  the  Al, A 2 , and a small piece 
of the B domain)  and a light  chain  (containing  the A3, C1, and 
C2 domains) that are associated  via a single Ca2+ ion (5, 6). 
Factor Va is a  nonenzymatic protein cofactor, which together 
with  the  serine  protease  factor Xa, Ca2+  ions, and a procoagu- 
lant  membrane  surface forms the  prothrombinase complex. De- 
pending on the  reaction conditions the presence of factor Va 
causes a 103-106-fold stimulation of the  rate of prothrombin 
activation  (7, 8). This  rate  enhancement  appears to  be caused 
by 1) an increase of the  catalytic  activity (kcat) of the  enzyme 
factor Xa (7, 8), 2) stimulation of the  binding of factor Xa to 
phospholipid membranes  (7, 9, lo), and 3) an increased  inter- 
action of the  substrate  prothrombin  with  the  prothrombinase 
complex (10). 
Snake venom proteins  have  been  shown  to be helpful tools in 
studying  structure-function  relationships of blood coagulation 
factors. Recently, we have purified a protease from the venom of 
Naja  nuju  oxiuna (11) that  is  able  to  activate  both  human  and 
bovine factor V. However, the factor Va molecule generated by 
this venom activator exhibited a much lower cofactor activity 
than  thrombin-activated  factor V. Actually, the venom protease 
can  also be regarded  as a factor Va inactivator because incuba- 
tion of thrombin-activated  human  factor Va with  the venom 
protease  resulted  in  an 80-90% loss of cofactor activity. 
In  the  present  paper we describe the  structural  and func- 
tional  properties of the  factor Va derivative  obtained  after  in- 
cubation of factor Va with  the venom protease.  It  is hown that 
the protease cleaves a 27-amino acid peptide (A~p~ '~ -Arg~ '~ )  
from the  carboxyl-terminal  part of the  heavy  chain of factor Va. 
The corresponding loss of cofactor activity  appears  to be caused 
by impaired  interaction of venom-treated  factor Va with pro- 
thrombin  and factor Xa. 
EXPERIMENTAL PROCEDURES 
Materials-Hepes, Tris, bovine serum  albumin, chicken  egg  albumin 
(ovalbumin), soybean trypsin inhibitor (type IS), bovine brain phos- 
phatidylserine, egg  yolk  phosphatidylcholine,  and  Russell's  viper  venom 
were purchased from Sigma. DOPC' and DOPS were obtained from 
Avanti Polar Lipids, Pelham, AL. The chromogenic substrates S2238 
and S2337 and the thrombin  inhibitor I2581 were  supplied by Chro- 
mogenix, Molndal, Sweden. D-Pro-Phe-Arg-CH,Cl was obtained from 
phocholine; factor Va,,, factor Va treated with the protease purified 
The abbreviations used are: DOPC, 1,2-dioleoyl-sn-glycero-3-phos- 
from N. naja oxiana venom; BSA, bovine serum albumin; 12581, N- 
D-Phe-(pipecolyll-Arg-p-nitroanilide; S2337, Ile-Glu-(piperidyll-Gly- 
dansyl-(p-guanidinol-phenylalanine-piperidide hydrochloride; S2238, 
Arg-p-nitroanilide; p-NPGB, p-nitrophenyl-p'-guanidinobenzoate hy- 
drochloride;  DOPS, 1,2-dioleoyl-sn-glycero-3-phosphoserine; RW-X, 
purified  factor X activator from Russell's  viper  venom. 
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Function of Heavy Chain of Human Factor Va 20663 
Calbiochem, andp-NPGB was from ~ u t r i t i o n ~  Bi~hemicals.  Fast pro- 
tein liquid chromato~aphy equipment and column materials used for 
protein purification were purchased from Pharmacia, Uppsala, Sweden. 
Protehs-Human coagulation factors used in  this study were is+ 
lated from fresh frozen plasma. Human prothrombin and factor X were 
purified according to DiScipio et aE. (12). Human thrombin was pre- 
pared from prothrombin activation mixtures as described hy Pletcher 
and Nelsestuen (13). Human factor Xa was ohtained from purified fac- 
tor X after activation with RW-X and isolation from the activation 
mixture by affinity chromatography on soybean trypsin inhibitor- 
Sepharose (14). RW-X was purified from  Russell’s viper  venom  accord- 
ing to Schifkan et al. (15). Human factor V was purified essentially as 
described by Dahlback (1) with minor modifications (16). Factor Va was 
obtained after activation of factor V with thrombin, separated from 
activation peptides on a prothrombin-CL4B-Sepharose column (171, and 
stored in a buffer containing 25 nm Hepes pH 7.5,100 mM NH,Cl, 5 mM 
CaCI,, and 5 mgiml BSA. The purified coagulation factors were stored 
at  -80 “C. Protein preparations were >95% pure as judged by SDS- 
~lyacrylamide gel electrophoresis according to Laemmli (18). 
Protein Concentrutions-Protein concentrations were d e t e ~ i n e d  ac- 
cording to Lowry et ai. (19). Molar thrombin and factor Xa concentra- 
tions were determined by active-site titration with p-NPGB (20, 21). 
Prothrombin concentrations were determined after complete activation 
of prothrombin with Echis curinatus venom and  quantitation of throm- 
bin with p-NPGB. Factor V concentrations were estimated from the 
absorbance at  280 nm using anAizo of 8.9 (2). Factor Va was quantitated 
as described beiow. 
High Performance Liquid Chromatography-Reversed-phase chro- 
matography was  performed on an Aquapore  C18  (2.1-mm internal di- 
ameter) column  connected  to a microbore  HPLC system from  Applied 
Biosystems at a flow rate of 200 pl/min. After application of the samples, 
the proteins and peptides were eluted with a linear gradient of solvent 
€3 (0.1% trifluoroacetic acid in 60% acetonitrile) in solvent A (0.1% 
trifluoroacetic acid). Proteins and peptides present in the eluate were 
detected by measuring the absorbance at  214  nm. Further details are 
given in the legend to Fig. 2. 
Amino-terminal Sequence  Analysis-200-pl samples containing 
either (a ) 6 pg of factor Va or (b j 6 pg of factor Va treated with 0.06 pg 
of venom protease or  (e) 0.06 vg of  venom protease were adsorbed onto 
Rospin  pol~inylidene difluoride filters (Applied  Biosystems), and the 
filters were washed by centrifugation with m e t h a n o ~ , O  (20:80f.  In the 
case of amino acid sequence analysis of peptide fractions obtained after 
HPLC  (cf:  Fig. 2) the peptide-containing fraction was freeze-dried, re- 
dissolved in 0.1% trifluoroacetic acid, and loaded  on  Polybrene-coated 
glass filters. 
The samples were subsequently subjected t o  automated amino-ter- 
minal sequencing on an Applied  Biosystems  model 476A pulsed liquid 
sequencer. 
Phospholipid Vesicle Preparations-Appropriate quantities of phos- 
pholipids  dissolved in chlorofodmethanol  (l:l, v/v)  were  mixed in a 
small glass tube. After drying under a mild  flow  of N, the phospholipids 
were suspended in 2 ml  of a buffer containing 25 IXIM Wepes  pH 7.5 and 
175 mM NaCl. The phospholipid suspension was  vigorously  vortexed  for 
1 min and subsequently sonicated for 10 min at 0 “C using an MSE 
Mark I1 150-watt ultrasonic disintegrator set  at 8 pm peak to peak 
amplitude. Phospho~pid concentrations were determined by phosphate 
analysis 122). 
Factor Va Assay-Factor Va was quantitated by determining the  rate 
of factor Xa-catalyzed prothmmbin activation in reaction mixtures that 
contained a limiting amount of factor Va and  saturating concentrations 
of phospholipid  vesicles (50 mf phosphatidylserine/phosphatidylcholine, 
1090, I&), factor Xa (5 n&, and prothrombin (0.5 p ~ )  (16). The molar 
factor Va concentration in the assay mixture was calculated fmm the 
rate of prothrombin activation using a turnover number of 6000 mol  of 
prothrombin activated per min per mol of factor Xa-Va  complex (23). 
Molar venom-treated factor Va (Va,,) concentrations were calculated 
from and taken  to be identical to the factor Va concentration initially 
present. 
The assay conditions were modified in experiments in which  differ- 
ences in cofactor activity between factors Va and Va, were  monitored. 
For optimal display of functional differences between factors Va and 
Va,,, the factor Va assay was performed at suboptimal factor Xa (0.5 
n d ,  phospholipid (5 p~ phosphatidylserin~phosphatidylcholine, 595, 
&MI, and prothrombin (0.25 pMj concentrations (see legend to Fig. 1). 
Kinetic Data Analysis-The formation of a membrane-bound factor 
Xa-Va complex was determined by measuring rates of prothrombin 
activation in  the presence of phospholipid  vesicles a t  a fixed (limiting) 
concentration of factor Xa and varying amounts of factor Va or  vice 
versa. Factor Xa, factor Va, and phospholipid  vesicles were preincu- 
bated for 5 min at 37 “C in 25 mrur Hepes pH 7.5, 175 mM NaCI, 2 mM 
CaGl,, and 5 mg/ml BSA. Prothromhin activation was started by the 
addition of prothrombin (preincubated at  37 “C in the same buffer). 
Rates of prothrombin activation were determined with the chromogenic 
substrate 52238 (8). The apparent Kd for  dissociation of the membrane- 
bound factor Xa-Va  complex and the prothrombin-converting 
activity of this complex at  [Factor Val--.m CYve,,) were ohtained from 
plots of the rate of prothrombin activation as a function of the factor Va 
or Xa concentration that were fitted to the equation for a single-site 
binding isotherm (hyperbola) via nonlinear least  squares analysis. 
The kinetic parameters (K,  and V,) for factor Xa-catalyzed  pro- 
thrombin activation were determined by measuring the rate of throm- 
bin formation at varying prothrombin concentrations in the presence of 
a fixed  phospholipid concentration, a limiting amount of factor Xa, and 
a saturating concentration factor Va or Va, as described in the previ- 
ous paragraph. The kinetic parameters were obtained by fitting the 
data to the Michaelis-Menten equation using nonlinear least  squares 
analysis. 
Binding Studies-Bind~ng parameters for factor Va-membrane asso- 
ciation were determined on planar phospholipid bilayers. The free fac- 
tor Va concentrations were determined with the f ~ c t ~ o n a ~  assay de- 
scribed  above, and the concentrations of membrane-bound factor Va 
were determined by ellipsometry (24). Amounts of phosphol~pid-~und 
factor Va were plotted as a function of the free factor Va Concentration, 
and the binding parameters (Kd and number of membrane binding 
sites) were obtained by fitting the  data  to  the equation for a single-site 
binding isotherm using nonlinear least  squares analysis. 
RESULTS 
Partial  Inactivation of Factor Vu by Protease  Purified  from 
Venom of N. naja oxiana-We recently purified an enzyme  from 
the venom of N. naja  oxiana that converts thrombin-activated 
factor V (factor Va) into a molecule with reduced cofactor  ac- 
tivity (11). The effects of the venom protease on the  structure 
and function of human factor Va were monitored with a func- 
tional assay (Fig. lA) and with SDS-polyacrylamide  gel  eiec- 
trophoresis analysis (Fig. 1B). Factor Va activity was deter- 
mined via its ability to  act as a cofactor in factor Xa-catalyzed 
prothrombin activation. To optimize the detection of functional 
differences between factor Va and factor Va,, the activity assay 
was performed at suboptimal factor Xa, prothrombin, and phos- 
pholipid concentrations (Fig. 1; also see “Experimental Proce- 
dures”). Incubation of factor Va with venom protease resulted 
in a rapid decrease of cofactor function until the activity 
reached a plateau at approximately 15% of the activity of na- 
tive factor Va (Fig. LA 1. SDS-polyacrylamide  gel electrophoresis 
analysis of factor Va before (Fig. lB ,  left lane) and  after incu- 
bation with venom protease (Fig. lB,  right  lane) shows that  the 
heavy chain of factor Va,, had a slightly increased electro- 
phoretic mobility, indicating the loss of a small peptide (M,  - 
4000) from the heavy chain. 
~ ~ i n o - t e r m i n a ~  Sequencing of Factor Vu and Factor 
Va,,--To gain more insight into the localization of the cleavage 
site in the factor Va molecule we subjected factor Va to  amino- 
terminal sequencing before and  after complete reaction with N. 
nuja  oxiana venom protease (Table I). The sequence data ob- 
tained for native factor Va indicated the presence of two 
polypeptide chains with amino-terminal sequences that  are  in 
agreement with the amino-terminal sequence reported for the 
heavy and  light chain of factor Va (3). 
After complete reaction of factor Va with venom protease a 
third amino terminus  (present  in about equal amounts) could 
be  deduced  from the sequence data. This new amino terminus 
does not originate from the venom enzyme since the  amount of 
venom protein present in  the reaction mixture was too low to be 
detectable in the sequence analysis (data not shown).  From the 
fact that only  one  new amino-terminal sequence was formed we 
conclude that a single peptide bond is cleaved in factor Va 
during incubation with the venom protease. The newly  formed 
amino-terminal sequence yields a unique match with the pub- 
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loo 1
A 
8o t 
0 1  I I I I I I 
0 10 20 30 40 50 
TIME (min) 
HC".,' 
- 200,000 
- 116,000 
- 97,400 
LC", " . - i  - 67,000 
- 46.000 
- 33.000 
FVa FVaNO 
- 
factor Va. Purified human factor Va (200 pg/ml) was  incubated  with 
FIG. 1. Effect of the N. nu& oziana venom protease on human 
purified N. naja oxiana venom protease (2 pg/ml) in 250 1.11 of 25 mM 
Hepes pH 7.5, 175 mM NaCl, and 5 mM CaCl, a t  37 "C. A, a t  the 
indicated time  points factor Va activity was determined in a  reaction 
mixture (37 "C) containing 25 mM Hepes pH 7.5, 175 mM NaCI, 2 mM 
CaCl,, 5 mg/ml bovine serum albumin, 0.5 nM factor Xa, 0.25 p~ pro- 
thrombin, 5 p~  brain phosphatidylserine/egg yolk phosphatidylcholine 
(595, d ~ ) .  Further  details of the  assay procedure are described under 
"Experimental Procedures." B,  before addition of venom protease (lane 
Fva) and  after complete reaction (50 min, lane FVa,,) 25-1.11 aliquots 
were taken for gel electrophoretic analysis on a 7.5% polyacrylamide 
slab gel  (5% stacking gel) in  the presence of sodium dodecyl sulfate  and 
5% 2-mercaptoethanol. The positions of the Va heavy chain ( H C )  and 
the light  chain doublet (LC)  are indicated  together  with the positions of 
molecular size markers  run on a separate lane on the gel. 
lished sequence of factor V at  Asp683-G1u690 (3), a region  located 
in the heavy chain domain of factor Va. 
HPLC of Factor V and Factor VaNo-Factor Va and factor 
Va,, preparations were subjected to reversed-phase chroma- 
tography. In  the case of factor Va a broad protein peak that 
elutes between 33 and 45 min presumably contains the heavy 
and light chains of factor Va (Fig. 2A ). A similar broad protein 
peak was observed in the factor Va,, preparation (Fig. 2B). 
However, the chromatogram of factor Va,, showed  one major 
additional peptide peak eluting at  24.6 min. This peptide peak, 
which was neither  present  in factor Va (Fig. 2 A )  nor in the 
purified venom protease preparation (data not shown), was 
collected  for sequence analysis. The amino acid  sequence of this 
peptide (Table 11) appeared to be identical to the  last 27 amino 
acids from the carboxyl-terminal part of the heavy chain of 
factor Va (3). The small peaks eluting between 28 and 32 min 
did not contain material that could  be sequenced. 
From these data we conclude that incubation of factor Va 
with the purified protease from N. naja oxiana venom resulted 
in cleavage of the peptide bond between His6R2 and Asp6".  Be- 
cause of this cleavage a peptide of 27 amino acids (with a 
calculated M, of about 3140) is removed. This is in reasonable 
agreement with the change in  apparent M ,  of the factor Va 
heavy chain observed in the SDS  gels after reaction of factor Va 
with venom protease (cf Fig. 1 B ) .  
Functional Properties of  Factor VaNo-Optimal  cofactor  ac- 
tivity of factor Va in prothrombin activation requires interac- 
tion of factor Va with procoagulant membranes, factor Xa, and 
prothrombin. To examine which of these functions was im- 
paired in N. naja oxiana-treated factor Va  we compared factor 
Va and factor Va,, in direct binding studies  and  in  a kinetic 
analysis of prothrombin activation. 
Fig. 3 shows an experiment in which we tested the ability of 
factors Va and Va,, to bind to a  planar lipid bilayer composed 
of  20  mol % DOPS in DOPC. Factors Va and Va,, bound  equally 
well to  the membrane, and half-maximal binding was observed 
at  2.2 nM factor Va and 1.7 nM factor Va,,. At saturating con- 
centrations of factors Va and Va,, the amounts of bound  pro- 
tein were 0.34 pg of factor Va/cm2  of phospholipid and 0.35 pg 
of factor Va,dcm2 of phospholipid, respectively. Considering 
that 1 cm2 of a phospholipid bilayer contains 0.4 pg of phos- 
pholipid and that  the molecular weights of factor Va and  the 
phospholipid used are -180,000 and -800,  respectively, it can 
be calculated that  the phospho1ipid:factor Va ratio (moVmo1) at 
saturation  is 265  for factor Va and 257  for factor Va,,. Thus, it 
appears that  the cleavage in the factor Va heavy chain by N. 
naja oxiana did not result  in a change in lipid binding proper- 
ties of the factor Va molecule. These data support  the concept 
that  it is the light chain region of factor Va that is actually 
responsible for lipid binding (25-28). 
To compare the ability of factors Va and Va,, to  assemble into 
a membrane-bound prothrombinase complex we determined 
initial steady-state rates of prothrombin activation at  a limited 
amount of factor Xa as a function of the factor Va or factor Va, 
concentration (Fig. 4A). Low amounts of factor Va were re- 
quired for full expression of prothrombinase activity, whereas 
much higher amounts of Va,, were needed in order to  obtain 
similar activation rates. Half-maximal prothrombinase com- 
plex formation was observed at  0.25 and 2.01 nM factor Va and 
factor Va,,, respectively. The double-reciprocal  plot  shown in 
Fig. 4B shows that  the intercepts at  the y-axis were approxi- 
mately the same for factors Va and Va,,. Thus, once formed the 
factor Xa-Va and factor Xa-Va, complexes are equally capable 
of activating prothrombin. 
With respect to the different cofactor activities of factor Va 
and Va, the possibility had to be ruled out that factor Va,, 
lacks functional activity and that  its cofactor activity is due to 
a small (-15%) remaining amount of factor Va. This possibility 
is excluded by the observations that 1) titrations of fixed  lim- 
iting amounts of factor Va or Va,, with factor Xa yield a K, 
of 0.24 and 2.27 nM for factor Xa-Va and Xa-Va,, complexes, 
respectively (Table 111) and 2) a functional factor Va assay 
performed at  saturating factor Xa (5 nM), prothrombin (3 p ~ ) ,  
and phospholipid  (50 p~ DOPS/DOPC,  20:80, M/M) yields iden- 
tical activities for factor Va and factor Va, (data not shown). 
We also determined the kinetic parameters of prothrombin 
activation at  a fixed factor Xa and phospholipid concentration 
and at  saturating concentrations of factor Va or Va,,. Fig. 5A 
shows the  rates of thrombin formation obtained for the factor 
Xa-Va and factor Xa-Va,, complexes as a function of prothrom- 
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Function of Heavy  Chain of Human Factor Va 20665 
TABLE I
Amino-terminal sequences of factor Vu before and  after  incubation  with  the uenom protease from N. naja  oxiana 
Human factor Va (30 pg/ml) was  incubated for 1 h at 37 “C in 25 mM Hepes  pH 7.5, 175 mM NaCl, 2 mM CaCl, either  in  the absence  or  presence 
of N. naja  oxiana venom protease (0.3 pg/ml). Both  factor Va samples  were  subjected  to  amino-terminal  sequencing  as  described  under  “Experi- 
mental  Procedures.” 
Factor Va Factor Va + N .  naja  oxi na 
Cycle Factor V residues 
no. Residue  Residue New Factor V residues 
1-8“ 1546-1553“ NH, terminus 683-690” 
pmol 
A (31.1) 
S (14.4) 
D (22.9)b 
Q (29.6) 
N (15.6) 
L (17.4) 
N (20.3) 
R (19.1) 
G (16.6) 
Q (16.1) 
N (19.1) 
F (13.4) 
Y (14.0) 
V (14.0) 
A (30.5) 
S (15.4) 
D (68.0) 
Q (39.6) 
N (18.7) 
R (10.6) 
L (22.7) 
N (19.7) 
R (22.6) 
G (16.5) 
E (13.4) 
Q (19.7) 
N (17.5) 
P (15.5) 
F (14.6) 
E (19.0) 
Y (12.5) 
V (16.0) 
E (19.8) 
pmol 
(D) 
R 
L 
E 
P 
E 
? 
E 
a Amino-terminal  sequence of the heavy  chain  (residues 1-8) and  light  chain  (residues 1546-1553) of factor Va (from Ref. 3). 
* Part of the  aspartic acid in  the first cycle is most  likely  accounted for by coelution of phenylisothiocyanate-NH,. 
A 
E 
2 
a 
N 
0 10 20 30 40 50 60 
Time (min) 
B 
0.5 . 
0.4 . 
0.3 . 
0.2 
0 .  
. 0.1 
. 
a 
I . - . . . . . . . . . . I  
0 10 20 30 40 50 60 
Time (min) 
tor Va,. Factor Va (250 nM) was  incubated for 10 min  in 25 mM Hepes 
FIG. 2. Reversed-phase chromatography of factor Va and fac- 
pH 7.5,175 mM NaCl, and 5 mM CaCl, a t  37 “C either  in  the  absence (A) 
or  presence ( B  of 1 pg/ml purified venom protease  from N. naja  oxiana. 
600 p1 of these mixtures were applied to an  Aquapore C18 column, 
concentrated for 10 min  with 0.1% trifluoroacetic acid in 12% acetoni- 
trile  and  eluted (40 min)  with a linear  gradient of acetonitrile (1248%) 
in 0.1% trifluoroacetic  acid. Further  details  are  given  under  “Experi- 
mental  Procedures.” 
TABLE I1 
Amino  acid sequence of peptide  isolated from factor Vu, 
preparations 
The peptide isolated from factor Va,, preparations (Fig. 2 8 )  was 
subjected  to  amino acid sequencing  as  described  under  “Experimental 
Procedures.” The amino acid sequence indicated was determined by 
automated call using the software supplied with the sequencer. The 
number  in  parentheses  indicates  the  background-corrected picomoles a t  
a  given cycle. It is  most  likely that  the first amino acid is Asp (9.6 pmol). 
It could not, however, be positively identified  because of impurities  in 
the first cycle. The last amino acid (Arg)  showed  a low yield caused by 
a strong  washout of the  last  residue. 
Cycle no. Amino acid Cycle no. Amino acid 
2 
1 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
pmol 
? 
R (6.4) 
E (17.8) 
L (24.7) 
P (12.8) 
E (11.6) 
D (7.4) 
E (9.8) 
E (11.3) 
S (1.3) 
D (5.2) 
A (9.2) 
D (7.2) 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
pmol 
Y (5.7) 
D (7.4) 
Y (8.0) 
Q (4.5) 
N (3.4) 
R (2.9) 
L (2.2) 
A (4.7) 
A (7.7) 
A (10.7) 
L (2.1) 
G (3.2) 
I(2.7) 
R (0.2) 
~~ 
bin  concentration. From the Lineweaver-Burk  plots  shown in 
Fig. 5B it can be concluded that the reaction adhered  to overall 
Michaelis-Menten  kinetics.  With the factor Xa-Va complex the 
reaction  was  characterized by a K,,, for prothrombin of 0.24 p~ 
and a V, of 6860 mol of prothrombin  activated  per  min  per 
mol of factor Xa. This is in reasonable  agreement with data 
reported  earlier (23,281. In  the  case of the factor Xa-Va,,  com- 
plex the K,,, was less favorable (0.83 p~), whereas V,, was 
slightly  higher (7685 mol of prothrombin  activated  per  min  per 
mol of factor Xa). 
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0.004 I 
0 2 4 6 0 10 
Factor Va or FactorVaNO (nM) 
FIG. 3. Binding of factor Va and Va,, to planar phospholipid 
bilayers. Binding of factor Va (0) and factor Va,, (A) to  planar  phos- 
pholipid bilayers (DOPSIDOPC, 20330, M/M) was  determined by ellip- 
sometry  (24)  in a buffer  containing  25 mM Hepes  pH  7.5 at 37  “C,  175 
mM NaCl, 2 mM CaCl,, and 5 mg/ml BSA. The solid lines represent 
hyperbolas obtained by a nonlinear  least  squares fit of the  data to  a 
single-site  binding  isotherm.  The  binding  parameters  describing  these 
hyperbolas are Kd(Va) = 2.2 n~ and 0.34 pg of factor Va bound  per cm2 
of phospholipid at saturating factor Va or KJVa,,) = 1.7 n~ and 0.35 pg 
of factor Va,, bound  per cm2 of phospholipid at saturating factor Va,,. 
25 
Va 
Y- 
O 2 4 6 0 I 0 1 2 1 4  
Factor Va or Factor VaNO (nM) 
B - 0.41 fvaNo 
m - 
S 
-5 0 5 10 15  20 
I/Factor Va or I/Factor VaNO (nk4-I) 
FIG. 4. Comparison  of cofactor activities of factor Va and Va,,. 
Initial  rates of prothrombin  activation  were  determined a t  37  “C at  a 
fixed, limiting concentration of factor Xa (3 PM) in 250 pl of buffer 
containing  25 mM Hepes  pH  7.5,  175 mM NaC1, 2 mM CaCl,, 5 mg/ml 
BSA, 25 p~ phospholipid vesicles (DOPSIDOPC, 5:95, M/M), 1 p~ pro- 
thrombin,  and  varying  amounts of factor Va (0) or Va,, (A) as described 
under  “Experimental  Procedures.” A, rate of prothrombin  activation  as 
a  function of factor Va or Va,, concentration.  The solid lines represent 
hyperbolas obtained  after  fitting  the  data  with KID,, = 0.25 n~ and Vva,, 
= 21.7 n~ IIdmin (0) and  with Kl,2vaNo = 2.01 nM and VvaNo+= = 16.9 nM 
IIdmin (A). B ,  double-reciprocal  plot of the  same  data. 
Dissociation of  Peptide  from Factor Va,,-It may be argued 
that  the  peptides  resulting from  cleavage of factor Va by the 
venom protease  remain associated with  the factor Va,, mole- 
cule through noncovalent interactions.  Unfortunately, no meth- 
ods are  available to  detect  the possible separation of the  peptide 
from factor Va,, at the low factor Va,, concentrations em- 
ployed in  the  kinetic  experiments. We were  able  to show, how- 
ever, that inactivation of high  concentrations of factor Va (250 
nM) with  the venom protease  and  subsequent gel filtration on a 
small  desalting column (9.1-ml Sephadex G-25M) resulted  in 
removal of the  majority (-70%) of the  peptide from the  factor 
Va,, fraction. This  indicates that the  peptide  is  in a normal 
association-dissociation equilibrium with factor Va,, at high 
TABLE I11 
Comparison of  functional properties of factors Vu and  Vu, 
This  table  summarizes  the  different  properties of factor Va and Va,, 
obtained  from  the  data  presented  in  Figs. 3-5. For details  see  text  and 
the legends to  the figures. 
Factor Va Factor Va, 
K,PL” 2.7 nM 1.7 nM 
nb 265 257 
K1,,,.va. 0.25 n~ 2.01 nM 
Kl/2Xa-Vad 0.24 n~ 2.27 n~ 
Km e 0.24 PM 0.83 PM 
kcate 114 s-’ 128 s-’ 
Dissociation  constant for membrane  factor Va or  membrane  factor 
Va complex (cf: Fig. 3). 
%hospholipid:factor Va or Va,, ratio (moVmo1) at saturation  with 
factor Va or Va,, (cf: Fig. 3). 
e Apparent dissociation constant for the membrane-bound factor 
Xa-Va or Xa-Va,, complex determined at limiting  factor Xa concentra- 
tions (cf: Fig.  4). 
Apparent dissociation constant for the membrane-bound factor 
Xa-Va or Xa-Va,, complex determined a t  limiting  factor VaNa,, con- 
centrations  (data  not  shown). 
e K,,, and k,,,, kinetic  parameters of prothrombin  activation by the 
factor Xa-Va or  factor Xa-Va,, complex (cf: Fig. 5). 
25 1 
OK I 
0 1 2 3 4 
Prothrombin (pM) 
-5 0 5 10 15  20 
l/Prothrombin (ph4-I) 
tion of prothrombin concentration. Initial rates of prothrombin 
FIG. 5. Prothrombin activation by  Xa-Va and Xa-Va,, as a func- 
activation  were  determined as described  under  “Experimental F’roce- 
mixture  (37  “C)  containing  25 mM Hepes  pH  7.5,  175 m~ NaCl,  2 mM 
dures” a t  a fixed, limiting  concentration of factor Xa (3 PM) in a  reaction 
CaCl,, 5 mg/ml BSA, 25 PM phospholipid vesicles (DOPSIDOPC, 5:95, 
&M), saturating  amounts of  Va (5 nM, 0) or Va,, (35 n ~ ,  A), and  varying 
amounts of prothrombin. A, initial  rate of activation  as a function of 
K, = 0.24 p~ and V,, = 6860 mol of IIdmidmol of factor Xa-Va (0) and 
prothrombin concentration.  The solid lines represent hyperbolas with 
with K,,, = 0.83 and V,, = 7685 mol of IIdmidmol of factor Xa-Va,, (A) 
that  were  obtained by fitting  the  data  to  the  Michaelis-Menten  equation 
using  nonlinear  least  squares  analysis. B,  Lineweaver-Burk  plots of the 
same  data. 
concentrations,  and  it  is likely that it will be  fully released from 
factor Va,, at the low concentrations employed in  the  kinetic 
experiments. 
DISCUSSION 
Factor Va exerts  multiple effects in factor  Xa-catalyzed pro- 
thrombin  activation.  The cofactor strongly  increases  the  cata- 
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lytic turnover (kcat) of the enzyme  factor Xa and promotes the 
assembly of productive enzyme-substrate complexes at the pro- 
coagulant  membrane by stimulating  the  binding of factor Xa 
and  prothrombin  to  the  membrane.  Thus,  it  appears that factor 
Va is a multifunctional  protein  that promotes prothrombin ac- 
tivation  via  interaction with phospholipids, factor Xa, and pro- 
thrombin.  The phospholipid binding  site of factor Va appears to  
be located  on the  light  chain (25-281, and  prothrombin  has been 
reported  to  interact  with  the  heavy  chain (171, whereas  both 
the  heavy  and  light  chains of factor Va have  been  implicated to  
interact  with  factor Xa (17,  29,  30). 
The  data  presented  in this paper give additional  insight  into 
the  domains of the Va molecule that are involved in  the  inter- 
action  with factor Xa and Prothrombin. Using a protease  puri- 
fied from the venom of N. naja  oxiana we obtained a factor Va 
molecule (factor Va,,) that lacks 27 amino acid residues from 
the carboxyl terminus of the  heavy  chain  and  that is further 
characterized by a greatly reduced cofactor activity. 
Table I11 summarizes  the  functional  properties of factor Va 
and factor Va,,. Both factor Va and  factor Va,, bind  equally 
well to negatively charged phospholipids. This is in agreement 
with  earlier  reports that indicate  that  the  heavy  chain of factor 
Va is not involved in membrane binding. The  apparent Kd for 
Xa-Va complex formation at   the phospholipid membrane is, 
however, about 1 order of magnitude  less favorable in  the  trun- 
cated  factor Va,, molecule (Table I11 and Fig. 4). This  strongly 
suggests that the carboxyl-terminal residues of the  heavy  chain 
are  important for the  interaction of factor Va with  factor Xa. 
Once  formed, the factor Xa-Va,, complex also has somewhat 
less favorable kinetic  parameters for prothrombin  activation as 
evidenced by the  increase in K,  for prothrombin (Table I11 and 
Fig. 5). The  ability of factor Va to  increase  the  enzymatic  turn- 
over (k,) of prothrombin  activation  is  not affected in  the factor 
Va,, molecule (Table 111). Thus,  the  final 27 carboxyl-terminal 
residues of the  factor Va heavy  chain do not  play a role in  the 
increase of the kcat of prothrombin  activation,  but  these  resi- 
dues  are  apparently involved in complex formation of factor Va 
with  both  factor Xa and  prothrombin. 
The  fact that the carboxyl terminus of the  factor Va heavy 
chain  plays a  role in  protein-protein  interactions  between fac- 
tor Va and  other  proteins  can be appreciated on the  basis of the 
primary  structure of factor Va. The carboxyl terminus of the 
heavy  chain of factor Va is highly acidic (3) and  can,  therefore, 
be expected to  be at the surface of the molecule and to be 
readily  available for interaction  with  other molecules. In  this 
respect it is interesting  to  note hat Kalafatis et al. (31) recently 
reported that the  heavy  chain of bovine factor Va can  be phos- 
phorylated at Ser690 and  that this phosphorylation renders  the 
molecule more susceptible to  inactivation by activated  protein 
C. No data  were given, however, on the effect of phosphoryla- 
tion on the  interaction of factor Va with  factor Xa or prothrom- 
bin. Whether  such phosphorylation can also occur in the  hu- 
man molecule is as  yet  also  unknown.  The  literature  data (3, 
31) emphasize, however, that this region of the  factor Va heavy 
chain  is accessible  for interaction  with  other macromolecules 
and  plays an important role in  the expression and  regulation of 
factor Va cofactor activity. 
The cleavage site at which the  protease purified  from N. naja 
oxiana venom cleaves factor Va ( H i ~ ~ ~ ' - A s p ~ ~ ~ )  is an  unusual 
target  site for proteolytic  enzymes. There  is, however, a report 
on an abnormal fibrinogen (in which Arg16  of the Aa-chain is 
replaced by His") that is cleaved by thrombin  after  this  histi- 
dine  residue (32). It is also possible that the His682-Asp683 bond 
is cleaved by an endoproteinase Asp-N (33) with specificity 
toward  the  particular  amino acid  sequence that is cleaved in 
the heavy chain of factor Va. I t  is interesting, therefore, to 
further  study this snake venom protease in order  to  gain more 
insight  into  the molecular basis for its proteolytic specificity. 
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